ACI HealthCare Ltd.

Office Address:

245 Tejgaon Industrial Area Dhaka-1208, Bangladesh.

Factory Location:

Sonargaon Museum Gate-1 Road, Treepordi, Sonargaon, Narayanganj, 1440, Bangladesh

OVERVIEW

ACI HealthCare Limited (AHL) was established on February 18, 2013, as a specialized public limited subsidiary of Advanced Chemical Industries (ACI) PLC, carrying forward a heritage that originated in 1973 when the organization operated as Imperial Chemical Industries (ICI PLC) Bangladesh. With this legacy, ACI HealthCare Limited (AHL) was formed with a clear purpose — to elevate Bangladesh’s pharmaceutical manufacturing capability to meet the standards of the world’s most stringent and regulated markets.

Our strategic mandate is centered on regulated-market manufacturing and global healthcare access, with particular focus on regions such as the United States, Europe, and other advanced international markets. This direction demands uncompromising quality, disciplined operational governance, and alignment with global regulatory bodies, including the US FDA and other internationally recognized authorities.

From Bangladesh to the World — Advancing Access with Quality and Trust.

We apply a lifecycle quality mindset — where every process is understood, every risk is evaluated, and every improvement is intentional.

Our goal is development that is predictable, scalable, stable, and globally acceptable — by design.

Our goal is clear: to expand global access to dependable, well-governed generic medicines — improving health outcomes and supporting the sustainability of healthcare systems worldwide.

We view contract manufacturing not as a transaction, but as a shared commitment to quality, responsibility, and patient well-being.

State-of-the-art Facility:

To enable this mission, ACI HealthCare Limited (AHL) has developed a state-of-the-art manufacturing campus on approximately 39 acres in Sonargaon, Narayanganj. The facility is engineered to support multi-product production under controlled and compliant manufacturing environments, validated systems, structured material flow, and data-governed operations. Guided by a disciplined quality culture and continuous improvement mindset, ACI HealthCare Limited (AHL) aims to position Bangladesh as a trusted contributor to global pharmaceutical supply chains, ensuring consistent quality, regulatory confidence, and sustainable healthcare access worldwide.

Mission:

ACI HealthCare Limited (AHL)’s mission is to achieve business excellence through quality by planning, implementing, controlling and improving the standards of its products & services for exceeding customer expectations on continuous basis.

Vision:

ACI HealthCare Limited (AHL)’s vision is to play a leading role in improving the quality of life and well-being of the people through responsible application of knowledge and skills.

Leadership & Governance:

ACI HealthCare Limited (AHL) is led by a governance philosophy that prioritizes accountability, regulatory discipline, and ethical decision-making. Our leadership framework is built to ensure that every operational, scientific, and strategic action reflects our commitment to patient well-being, product quality, and responsible growth. We foster a culture where people are empowered to perform with clarity of purpose, clear role ownership, and an unwavering adherence to compliance expectations in regulated global markets. As a public limited subsidiary of ACI PLC, our governance structure integrates corporate transparency, data integrity, and performance oversight consistent with internationally recognized standards. Decision-making is guided by structured risk evaluation, policy adherence, and continuous improvement principles. This strong governance foundation enables ACI HealthCare Limited (AHL) to operate with confidence, meet global regulatory expectations, and uphold the trust placed in us by healthcare professionals, partners, regulators, and the communities we serve.

Regulated Market Expertise

ACI HealthCare Limited is structured to operate within regulated and quality-driven global markets, with established and expanding engagement across the United States, Europe, the Middle East and North Africa, Asia Pacific, and Latin America. Our operating model emphasizes regulatory alignment, reliable supply performance, and lifecycle quality governance, enabling sustainable participation in diverse international healthcare systems. Looking ahead, our strategic growth priorities include biosimilars, select API backward integration, and advanced delivery and control-release platforms — strengthening our capability to support complex, high-value, and globally relevant therapeutic solutions.

GMP Accreditations